KBY Biotech Indexv0.0.34
Search
← Pipeline|Geliglumide

Geliglumide

Phase 2/3
PAC-5772
By Pacific Biosciences
Source: Trial-derived·Trials: 1
Modality
mRNA
MOA
RAS(ON)i
Target
TIM-3
Pathway
Autophagy
PNHMCLEpilepsy
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
Mar 2019
→ Mar 2029
Phase 2Current
NCT06672560
2,241 pts·MCL
2019-03→2029-03·Completed
2,241 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-032.9y awayPh3 Readout· MCL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2029-03-03 · 2.9y away
MCL
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06672560Phase 2/3MCLCompleted2241OS
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
REG-6699RegeneronPhase 2/3TIM-3FcRni
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
NidasacituzumabUnited TherapeuticsPhase 1/2TIM-3ALKi
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
LiratinibKrystal BiotechNDA/BLATIM-3EZH2i
DoxazasiranAxsomePhase 1TIM-3IL-17i